REVIVE
To determine whether azithromycin is an effective and safe intervention for reducing excess mortality in adults with advanced HIV (CD4 ≤ 100 cells/mm³).
Project Details
Principal Investigator
Stéphane N’Goran
Duration
43 months
Sponsor
Population Health Research Institute of Hamilton Health Sciences Corporation (PHRI)
Study start
07 Jun 2024
Objectives
Main Objectives
Secondary Objectives
A multicenter, randomized, double-blind, placebo-controlled trial of azithromycin prophylaxis in patients with advanced HIV
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Estimated response time: 3-5 business days.
